Anika Therapeutics, Inc. (ANIK) Tops Q1 Revenue Tops Views
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.81 -1.05%
EPS Growth %: -125.0%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -125.0%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q1 EPS of $0.97, $0.72 better than the analyst estimate of $0.25. Revenue for the quarter came in at $34 million versus the consensus estimate of $16.03 million.
For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- B.Riley Assumes Anika Therapeutics (ANIK) at Buy
- Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
